SALIX PHARMACEUTICALS LTD - FORM 8-K - EX-99.2 - PRESS RELEASE DATED FEBRUARY 23, 2011, ANNOUNCING PRESENTATION AT THREE HEALTH - February 28, 2011

Attached files

file filename
8-K - FORM 8-K - SALIX PHARMACEUTICALS LTDd8k.htm
EX-99.3 - PRESS RELEASE DATED FEBRUARY 23, 2011, ANNOUNCING A CONFERENCE CALL TO PROVIDE - SALIX PHARMACEUTICALS LTDdex993.htm
EX-99.4 - PRESS RELEASE DATED FEBRUARY 24, 2011, ANNOUNCING ANTICIPATION OF RECEIVING - SALIX PHARMACEUTICALS LTDdex994.htm
EX-99.1 - PRESS RELEASE DATED FEBRUARY 28, 2011, REPORTING OPERATING RESULTS - SALIX PHARMACEUTICALS LTDdex991.htm

Exhibit 99.2

FOR IMMEDIATE RELEASE

 

Contact:    Adam C. Derbyshire    G. Michael Freeman
   Executive Vice President    Associate Vice President, Investor Relations
   and Chief Financial Officer    and Corporate Communications
   919-862-1000    919-862-1000

SALIX PHARMACEUTICALS TO PRESENT AT

THREE INVESTMENT CONFERENCES IN MARCH

RALEIGH, NC, February 23, 2011 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at three health care investment conferences during March 2011. Information of these conferences is provided below:

RBC Capital Markets’ Healthcare Conference

 

New York, NY   Wednesday, March 2, 2011   9:00 a.m. ET

ROTH 23rd Annual Orange County Growth Stock Conference

 

Dana Point, CA   Tuesday, March 15, 2011   9:00 a.m. ET

Barclays Capital 2011 Global Healthcare Conference

 

Miami, FL   Thursday, March 17, 2011   9:00 a.m. ET

Interested parties can access a live audio web cast of these presentations at http://www.salix.com. A replay of the presentations will be available at the same location.

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company’s gastroenterology specialty sales and marketing team.

Salix markets XIFAXAN® (rifaximin) tablets 200 mg and 550 mg, MOVIPREP® (PEG 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid for Oral Solution), OSMOPREP® (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) Tablets, VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets, APRISO™ (mesalamine) extended-release capsules 0.375 g, METOZOLV® ODT (metoclopramide HCl), PEPCID® (famotidine) for Oral Suspension, Oral Suspension DIURIL® (Chlorothiazide), AZASAN® (Azathioprine) Tablets, USP, 75/100 mg, ANUSOL-HC® 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC® 25 mg Suppository (Hydrocortisone Acetate), PROCTOCORT® Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT® Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 mg. Crofelemer, budesonide foam and rifaximin for additional indications are under development.

For full prescribing information and important safety information on Salix products, including BOXED WARNINGS for VISICOL, OSMOPREP and METOZOLV, please visit www.salix.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at 919 862-1000.

Salix trades on the NASDAQ Global Select Market under the ticker symbol “SLXP”.

For more information, please visit our Website at www.salix.com or contact the Company at 919-862-1000. Follow us on Twitter (@SalixPharma) and Facebook (www.facebook.com/SalixPharma). Information on our web site is not incorporated in our SEC filings.

Stock widget

Investing forum

SALIX PHARMACEUTICALS LTD Reports